Vial Logo

Updates

Search
All Resources
Press Releases
Videos

Vial Announces Dosing of First Participants in Phase 1 Healthy Volunteer Trial of VIAL-TL1A-HLE, a Novel Subcutaneous Half-Life Extended Anti-TL1A Antibody for the Treatment of IBD and Other Inflammatory Diseases

Read Article

Vial Announces Dosing of First Participants in Phase 1 Healthy Volunteer Trial of VIAL-TL1A-HLE, a Novel Subcutaneous Half-Life Extended Anti-TL1A Antibody for the Treatment of IBD and Other Inflammatory Diseases

Read Article